REVOLUTION MEDICINES INC is facing a surge in demand for its experimental pancreatic cancer drug following a survival-doubling clinical trial. The United States FDA authorized an expanded access program on May 1 to provide the oral pill, daraxonrasib, to patients with advanced disease. This early access bridge precedes a potential expedited approval that could finalize within months of a formal filing.

Survival Data Triggers Patient Influx